Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that it has received marketing approval in Hong Kong for its HT Supreme drug-eluting stent system. The system is now approved for use in symptomatic heart disease patients to improve the coronary artery lumen diameter caused by primary coronary artery lesions of up to 40 millimeters in length, with a reference vessel diameter ranging from 2.25 to 5.00 millimeters.
The HT Supreme drug stent is a next-generation product based on the company’s “Healing window period” theory, which focuses on improving patient wound healing speed and accelerating the functional recovery of the vascular endothelium post-stent implantation. The system is designed to achieve precise release of anti-proliferative drugs and polymer degradation through patented drug release curves, minimizing the impact on endothelial layer functional healing, thus balancing the reduction of restenosis rates. Additionally, it aims to reduce the long-term catch-up effect and the incidence of adverse events associated with traditional drug-coated stents (DES), enhancing the product’s long-term safety.
The HT Supreme drug-coated coronary artery stent system is a drug-device combination product. It comprises a drug-coated expandable cobalt chromium (CoCr) alloy coronary artery stent and a balloon delivery system. The stent’s scaffold is coated with a non-corrosive polymer layer at the bottom and a biodegradable polymer layer on the surface for drug release. The drug-eluting layer consists of a mixture of sirolimus and biodegradable polymers, and the stent is transported using a rapid exchange balloon expandable conveyance system.- Flcube.com
